Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

KalVista Pharmaceuticals (KALV) EBITDA (2016 - 2025)

KalVista Pharmaceuticals' EBITDA history spans 11 years, with the latest figure at -$55.2 million for Q2 2025.

  • For Q2 2025, EBITDA fell 23.16% year-over-year to -$55.2 million; the TTM value through Apr 2025 reached -$182.0 million, down 43.22%, while the annual FY2025 figure was -$185.2 million, 45.72% down from the prior year.
  • EBITDA for Q2 2025 was -$55.2 million at KalVista Pharmaceuticals, down from -$42.1 million in the prior quarter.
  • Across five years, EBITDA topped out at -$12.7 million in Q1 2021 and bottomed at -$55.2 million in Q2 2025.
  • The 4-year median for EBITDA is -$34.3 million (2024), against an average of -$34.6 million.
  • The largest annual shift saw EBITDA tumbled 58.36% in 2024 before it fell 23.16% in 2025.
  • A 4-year view of EBITDA shows it stood at -$12.7 million in 2021, then tumbled by 122.99% to -$28.2 million in 2023, then crashed by 49.16% to -$42.1 million in 2024, then crashed by 31.2% to -$55.2 million in 2025.
  • Per Business Quant, the three most recent readings for KALV's EBITDA are -$55.2 million (Q2 2025), -$42.1 million (Q4 2024), and -$39.8 million (Q3 2024).